Ablative Solutions, Inc.   Report issue

For profit Phase 2
Founded: Kalamazoo MI United States (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2016
NCT02910414
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Ablative Solutions, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

ethanol (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Essential Hypertension (Phase 2)

Hypertension (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1